you are here:

SMS Pharmaceuticals Ltd.

BSE: 532815 | NSE: SMSPHARMA |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE812G01025 | SECTOR: Pharmaceuticals

BSE Live

Dec 06, 14:14
127.70 -0.75 (-0.58%)
Volume
AVERAGE VOLUME
5-Day
7,504
10-Day
10,208
30-Day
10,260
988
  • Prev. Close

    128.45

  • Open Price

    128.75

  • Bid Price (Qty.)

    127.30 (1)

  • Offer Price (Qty.)

    127.65 (9)

NSE Live

Dec 06, 14:14
127.60 -1.10 (-0.85%)
Volume
AVERAGE VOLUME
5-Day
59,452
10-Day
90,673
30-Day
100,033
20,017
  • Prev. Close

    128.70

  • Open Price

    129.70

  • Bid Price (Qty.)

    127.40 (46)

  • Offer Price (Qty.)

    127.60 (84)

Company History - SMS Pharmaceuticals
We were originally incorporated as S.M.S. Pharmaceuticals Pvt. Ltd. 
 on December 14, 1987 for the manufacture of Bulk Drugs. Mr. K G 
 Suggula was our original promoter of our company. We had 
 accumulated losses till 1990, when our current promoters viz. Mr.
 Ramesh 
 Babu Potluri and Mr. T V V S N Murthy acquired the Company. The
 reason behind acquiring a loss making company was to avoid all the 
 regulatory formalities to be fulfilled in case of starting up a new
 unit.
 
 On November 2, 1994 our company was converted to Public Limited 
 Company from private limited and the name was changed to S.M.S. 
 Pharmaceuticals Limited. Subsequently on April 12, 2004 for
 operational 
 purpose our name was changed to SMS Pharmaceuticals Limited from 
 S.M.S. Pharmaceuticals Limited.
 
 We started with 20 employees as a single unit and single product
 Company 
 in 1990 and have now grown into a multi-location, multi-product
 Company 
 with 4 units and 310 employees on rolls and four Units. 
 
 In the year 1991 we started the manufacturing of bulk drug business
 with 
 the product called Ranitidine HCL at Unit I situated at IDA
 Khazipally, Jinnaram 
 Mandal, Medak District, Andhra Pradesh with a production capacity of
 3 metric 
 tonnes per annum and the process consisting of 7 major stages. As of
 today the 
 installed manufacturing capacity has expanded to 1,440 metric tonnes
 per annum 
 and the technology has also been upgraded to a 4-stage process, which
 has 
 enabled us to become a competitive seller in the market.
 
 We acquired a second Unit at Bachipally, Miyapur, Rangareddy
 District, Andhra 
 Pradesh in the year 2000 as part of the expansion programme, and
 started producing 
 Sumatriptan Succinate for which a non-infringing root of synthesis
 was developed 
 through in-house R&D. Currently Unit II is used to manufacture high
 value & Low 
 volume APIs like Sumatriptan Succinate, Ramipril and Quinapril.
 
 We started a Nutraceuticals and health care division (Unit III) as a
 part of 
 diversification in the year 2003, by launching an OTC product called
 Fenudiet and 
 Hearty Salt in consumer market. Fenudiet is a product for diabetics
 and we have 
 made an application with the Trade Mark Authority to get our brand
 Fenudiet 
 registered.. Subsequently we started manufacturing many other
 products like Alvit, 
 Set Free, De- Mass, and others. However, apart from Fenudiet & Hearty
 Salt, 
 manufacturing of products like Alvit, Set Free, De- Mass, and others
 have been
 discontinued because of high overheads cost on distribution and low
 margins.
 
 We have also started UNIT IV at Gagillapur (Village) Quthbullapur
 (Mandal Ranga 
 Reddy (Dist). in the year 2004 for scaling up of the APIs. This unit
 is to be used as 
 a pilot plant. 
 
 We have also expanded our R&D activities to have 4 PhDs supported 
 by more than 30 senior chemists. In the year 2004 we started an
 exclusive basic 
 research facility at Sanath Nagar, Hyderabad. The R&D center mainly
 focuses on
 anti-cancer molecules, anti-migraine molecules, anti-bacterial,
 anti-ulcer, important 
 intermediates and natural plant extracts. We are also having 2 more
 PhDs which 
 are looking after our production facilities at Unit I and & Unit II.
 
 We have filed 6 non-infringing process patents and 1 product patent
 under PCT and 
 10 process patent under Indian Patent Laws as detailed under the head
 Intellectual 
 Property in this Red Herring Prospectus. We have also filed
 DMFs/CoSs in US, Europe 
 and Canada for 4 products as listed under the head Intellectual
 Property mentioned
 in this Red Herring Prospectus. We also started producing ACE
 inhibitors Ramipril, 
 Quinapril and anti- cancer drug Gemcitibine.
 
 We had received in principle approvals from BSE vide letter dated
 December 21, 2004 
 and NSE vide letters dated January 11, 2005, May 31, 2005 and July
 12, 2005 and had 
 also received the observation letter from SEBI dated May 11, 2005 for
 launch of an IPO 
 for financing the same project envisaged in this RHP. However we did
 not proceed
 with the IPO. By the time we received the observation letter from
 SEBI our plans 
 underwent  some change since we perceived better opportunity in
 implementing a 
 bigger project with larger capacities and for the manufacture of few
 more products. Hence 
 we decided not to go ahead with the IPO.
 
 Our Milestones
 
 History and Major Events:
 
 Year         Events
 
 1987   ..   Incorporated by Mr. K G Suggula
 
 1988   ..   Issued 49,960 equity shares at the price of Rs. 10 per
 share
 
 1989   ..   Issued 50,000 equity shares at the price of Rs. 10 per
 share
 
 1990   ..   Acquired by present promoters Mr. Ramesh Babu Potluri &
 Mr. T V V S N 
                 Murthy Issued 50,000 equity shares at the price of
 Rs. 10 per share
 
 1991   ..  Commercial production of Ranitidine HCL with 3 MTPA at
 Unit I
 
 1992   ..   Ranitidine capacity increased to 180 MTPA Issues 150,000
 equity shares 
                 at the price of Rs. 10 per share
 
 1994   ..   Issued Bonus Shares in the ratio of 8:3 i.e.800,000
 equity shares of Rs. 10/- 
                 each Issues 150,000 equity shares at the price of Rs.
 10 per share and 350,000 
                 equity shares at the price of Rs. 60 per share
             --  Setup of in-house R&D laboratory in Unit I
 
 1995    ..  Doubled Ranitidine capacity to 360 MTPA Issued 450,000
 equity shares at the 
                 price of Rs. 120 per share
 
 1997   ..   Increased Ranitidine capacity to 720 MTPA
 
 1998   ..   Awarded the prestigious Pandit Jawaharlal Nehru Silver
 Rolling Trophy for its 
                 excellence as Best Industrial Productivity effort in
 the State
 
 1999   ..   Additional APIs Naproxen, Ciprofloxacin at Unit I
 
 2000   ..   Ranitidine capacity including intermediates increased to
 1,440 MTPA Acquired 
                 plant of high value APIs at Bachupally (Unit II)
 
 2001   ..   Commercial production of Sumatriptan Succinate at Unit
 II
            ..   ISO 9001:2000 certification obtained for Unit I
            ..   Recognized as export house by Ministry of Commerce
 
 2002   ..   Setup of in-house R&D laboratory in Unit II
            ..   US DMF filed for Sumatriptan Succinate
 
 2003   ..   ISO 9001:2000 certification obtained for Unit II
            ..   Supply Agreement with Ranbaxy under Para IV of ANDA
 for 
                 Sumatriptan Succinate
            ..   4 process patents and 1 product patent filed under
 the Patent 
                 Co-operation Treaty
            ..   1 Process Patent filed for Sumatriptan Succinate
 under European Patents.
            ..   Set up of Nutraceutical plants in Unit III
 
 2004   ..   USFDA approval obtained for Unit II
            ..   Commenced commercial production of Ramipril and
 Quinapril at Unit II
            ..   Established exclusive basic research facility at
 Sanath Nagar, Hyderabad
            ..   US DMF for Ranitidine HCL and CoS filed for
 Sumatriptan Succinate and Ramipril
            ..   Agreement entered into with IICT, Hyderabad for
 development of process 
                 know-how for Diltiazem HCL and Taxol C-13
            ..   Agreement entered into with IIT, Guwahati for
 development of process know-how 
                 for metal acetylacetonates
            ..   Entered into a Memorandum of Understanding with
 Sochinaz SA for exclusive 
                 development and supply of Trandolapril for global
 marketing by Sochinaz SA.
            ..   Setup of pilot plant facility for APIs at Gagilapur,
 Hyderabad (Unit IV)
            ..   1 process patents filed under the Patent Co-operation
 Treaty and 2 process 
                 patents filed with Indian Patents Office
            ..   Issued Bonus Shares in the ratio of 1:1 i.e.4,100,000
 equity shares of Rs. 5/- each
 
 2005   ..   8 process patents filed with Indian Patents Office
            ..   Commenced commercial production of Almotriptan in
 Unit II
            ..   US DMF filed for Ranitidine USP, Almotriptan and
 Ramipril.
            ..   Commencement of development of Trandolapril product
 under Contact Research 
                 for a European Company Sochinaz S/A.
 
 2006    ..  Published European Patent for Sumatriptan Succinate
             ..  Issued 2,923,000 equity shares to the shareholders of
 Sreenivasa Pharma Private 
                 Limited in exchange of shares of Sreenivasa Pharma
 Pvt. Limited.
             ..  Completion of contract research assignment of
 Trandolapril exclusively executed 
                  for Sochinaz SA 
             ..  CoS for Ranitidine HCL obtained from EDQM.
 
 2007    ..  Issued 400,000 equity shares at the price of Rs. 350 per
 share to Gulf 
                 Pharmaceutical Industries, a public shareholding
 company having its registered 
                 office at UAE
 
 2010
 
 - SMS Pharmaceuticals Ltd has appointed Mr. N. Rajendra Prasad as
 Chief Financial Officer (CFO) of the Company.
 
 2011
 
 - Mr. K. Umamaheswaram, Deputy General Manager, is appointed as
 Nominee Director of the Company.
 
 - The Board has recommended dividend of Rs. 1.50 (Rupee One and Fifty
 Paisa Only) per equity share of Rs. 10/- each on the paid up share
 capital of the company.
 
 2012
 -SMS Pharmaceuticals Appointed Mr. Utpal Gokhale, as a new nominee
 Director.
 
 2013
 -SMS Pharmaceuticals has recommended dividend of Rs. 2.00 (Rupee Two
 Only) per equity share of Rs. 10/- each.
 
 2014
 -SMS Pharmaceuticals has recommended dividend of Rs. 2.00 (Rupee Two
 Only) per equity share of Rs. 10/- each.
 
 2015
 - SMS Pharmaceuticals Limited has won India Pharma bulk drug company
 of the year award.
 - SMS Pharmaceuticals has splits its face value from Rs. 10 to Rs. 1